glycine has been researched along with Metabolic Syndrome in 11 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glycine supplementation improves various components of metabolic syndrome including diabetes, obesity, hyperlipidemia and hypertension." | 9.22 | Effects of glycine on metabolic syndrome components: a review. ( Hossenzadeh, H; Imenshahidi, M, 2022) |
| "Glycine (Gly) lowers hypercholesterolemia, hypertriglyceridemia and hypertension but its role in preventing adipocyte hypertrophy and modulating enzymatic activity of adipocytes has not been studied." | 7.83 | Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model. ( Castro, ES; Díaz-Díaz, E; Espejel, RV; Lans, VG; López, YR; Pérez-Torres, I; Zúñiga-Muñoz, A, 2016) |
| "Glycine plays an important role in balancing the redox reactions in the human body, thus protecting against oxidative damage in MetS patients." | 6.78 | Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure. ( Baiza-Gutman, LA; Cruz, M; Díaz-Flores, M; Duran-Reyes, G; Gaja-Rodriguez, O; Hernández-Saavedra, D; Kumate, J; Loza-Rodríguez, H; Munguia-Miranda, C; Pulido-Casas, E; Torres-Ramírez, N, 2013) |
| "Glycine supplementation improves various components of metabolic syndrome including diabetes, obesity, hyperlipidemia and hypertension." | 5.22 | Effects of glycine on metabolic syndrome components: a review. ( Hossenzadeh, H; Imenshahidi, M, 2022) |
| "Glycine (Gly) lowers hypercholesterolemia, hypertriglyceridemia and hypertension but its role in preventing adipocyte hypertrophy and modulating enzymatic activity of adipocytes has not been studied." | 3.83 | Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model. ( Castro, ES; Díaz-Díaz, E; Espejel, RV; Lans, VG; López, YR; Pérez-Torres, I; Zúñiga-Muñoz, A, 2016) |
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| "Glycine plays an important role in balancing the redox reactions in the human body, thus protecting against oxidative damage in MetS patients." | 2.78 | Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure. ( Baiza-Gutman, LA; Cruz, M; Díaz-Flores, M; Duran-Reyes, G; Gaja-Rodriguez, O; Hernández-Saavedra, D; Kumate, J; Loza-Rodríguez, H; Munguia-Miranda, C; Pulido-Casas, E; Torres-Ramírez, N, 2013) |
| "Glycine and AC10 were specific metabolites representative of discrimination according to sex-dependent MetS." | 1.72 | Targeted Metabolomics Revealed a Sex-Dependent Signature for Metabolic Syndrome in the Mexican Population. ( Canizales-Quinteros, S; Flores, YN; Ibarra-González, I; León-Reyes, G; Palacios-González, B; Rivera-Paredez, B; Salmerón, J; Vela-Amieva, M; Velázquez-Cruz, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Imenshahidi, M | 1 |
| Hossenzadeh, H | 1 |
| Ye, Z | 1 |
| Zhang, C | 1 |
| Wang, S | 1 |
| Zhang, Y | 1 |
| Li, R | 1 |
| Zhao, Y | 1 |
| Qiao, J | 1 |
| Palacios-González, B | 1 |
| León-Reyes, G | 1 |
| Rivera-Paredez, B | 1 |
| Ibarra-González, I | 1 |
| Vela-Amieva, M | 1 |
| Flores, YN | 1 |
| Canizales-Quinteros, S | 1 |
| Salmerón, J | 1 |
| Velázquez-Cruz, R | 1 |
| Díaz-Flores, M | 1 |
| Cruz, M | 1 |
| Duran-Reyes, G | 1 |
| Munguia-Miranda, C | 1 |
| Loza-Rodríguez, H | 1 |
| Pulido-Casas, E | 1 |
| Torres-Ramírez, N | 1 |
| Gaja-Rodriguez, O | 1 |
| Kumate, J | 1 |
| Baiza-Gutman, LA | 1 |
| Hernández-Saavedra, D | 1 |
| López, YR | 1 |
| Pérez-Torres, I | 2 |
| Zúñiga-Muñoz, A | 1 |
| Lans, VG | 1 |
| Díaz-Díaz, E | 2 |
| Castro, ES | 1 |
| Espejel, RV | 1 |
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Dravecká, I | 1 |
| Lazúrová, I | 1 |
| Habalová, V | 1 |
| Ibarra, B | 1 |
| Soria-Castro, E | 1 |
| Torrico-Lavayen, R | 1 |
| Pavón, N | 1 |
| Flores, PL | 1 |
| Infante, O | 1 |
| Baños, G | 1 |
| Ambye, L | 1 |
| Rasmussen, S | 1 |
| Fenger, M | 1 |
| Jørgensen, T | 1 |
| Borch-Johnsen, K | 1 |
| Madsbad, S | 1 |
| Urhammer, SA | 1 |
| Fiévet, C | 1 |
| Fruchart, JC | 1 |
| Staels, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters: A Clinical and Ex-vivo Study.[NCT03850314] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for glycine and Metabolic Syndrome
| Article | Year |
|---|---|
Effects of glycine on metabolic syndrome components: a review.
Topics: Exercise; Glycine; Humans; Life Style; Metabolic Syndrome; Obesity | 2022 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, B | 2006 |
1 trial available for glycine and Metabolic Syndrome
| Article | Year |
|---|---|
Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure.
Topics: Administration, Oral; Adult; Antioxidants; Biomarkers; Blood Pressure; Catalase; Dietary Supplements | 2013 |
8 other studies available for glycine and Metabolic Syndrome
| Article | Year |
|---|---|
Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances.
Topics: Alanine; Amino Acids; Body Mass Index; Female; Glycine; Humans; Insulin Resistance; Lysine; Metaboli | 2022 |
Targeted Metabolomics Revealed a Sex-Dependent Signature for Metabolic Syndrome in the Mexican Population.
Topics: Carnitine; Citrulline; Cohort Studies; Female; Glycine; Humans; Male; Metabolic Syndrome; Metabolomi | 2022 |
Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Pressure; Fatty Acids; Glycine; Hypertrophy; Insulin; Lip | 2016 |
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
The prevalence of Gly972Arg and C825T polymorphisms in Slovak women with polycystic ovary syndrome and their relation to the metabolic syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Genotype; Glycine; Heterotrimeric GTP-Binding Protein | 2010 |
Effect of glycine on the cyclooxygenase pathway of the kidney arachidonic acid metabolism in a rat model of metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Blood Pressure; Body Weight; Disease Models, An | 2011 |
Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome.
Topics: Adult; Aged; Alleles; Denmark; Female; Gene Frequency; Genotype; Glycine; Heat-Shock Proteins; Human | 2005 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Piogl | 2005 |